HOUSTON--(BUSINESS WIRE)--Houston-based biotechnology company Celltex Therapeutics Corporation is proud to announce a partnership with the Arthritis Foundation South Central Region. The coming together of these organizations marks a milestone for the future of regenerative medicine for people who are living with arthritis.
Founded in 2011 by David Eller and internationally-known spine surgeon, Dr. Stanley Jones, Celltex has been generating breakthroughs in the autologous (one's own) stem cell field to improve the quality of life for those suffering from injuries or vascular, degenerative and autoimmune diseases like arthritis. In an effort to help those with arthritis discover a new treatment option, Celltex has partnered with the Arthritis Foundation South Central Region, an organization that represents millions of people who are living with arthritis – some of whom have found relief in the use of their own stem cells.
The Arthritis Foundation continues to support new and more effective interventions to fight arthritis. “We are excited about the groundbreaking advancements in adult stem cell research leading toward new treatments and therapies for arthritis patients,” says Fiona Cunningham, director of community advancement for the Arthritis Foundation South Central Region. We are proud and honored to partner with Celltex and companies like them who demonstrate their commitment to bring the future of stem cell technology for arthritis and related diseases to the United States.”
Scientists and researchers have long seen mesenchymal stem cells (MSCs) as an attractive candidate for cell-based therapy for the treatment of arthritis, due to the anti-inflammatory and immunologic properties of MSCs. Celltex utilizes a patented processing and banking method that ensures the integrity and uniformity of an individual's MSCs, which are then multiplied in volumes never before possible, allowing for the creation of quantities necessary for therapeutic applications. The company processes and banks the cells, then releases the cells to a licensed physician in an approved facility for use in stem cell therapy.
“Celltex and the Arthritis Foundation have come together because of our shared mission, which is to help reduce the unacceptable pain, disability and other burdens of arthritis and related diseases. My own personal experience with autoimmune arthritis nearly ended my career. After facing so much failure with conventional medicine, it was only by receiving my own stem cells that I finally found relief. Four months after receiving therapy, I had my life back. I returned to work and my normal schedule, and I was inspired to bring this technology to the United States to help people who share my story,” says Celltex Chief Medical Officer, Dr. Stanley Jones.
The three states and nine offices of the South Central Region of the Arthritis Foundation work to improve the lives of more than 5.1 million adults and children who struggle every day with this serious health epidemic.
Striking one in every five adults and 300,000 children, arthritis is the nation’s leading cause of disability. The Arthritis Foundation (www.arthritis.org) is committed to raising awareness and reducing the impact of this serious, painful and unacceptable disease, which can severely damage joints and rob people of living life to its fullest. The Foundation funds life-changing research that has restored mobility in patients for more than six decades; fights for health care policies that improve the lives of the millions who live with arthritis; and partners with families to provide empowering programs and information.
Celltex Therapeutics Corporation is a private biotechnology company dedicated to generating breakthroughs in regenerative medicine, specifically in the autologous stem cell field, to effectively improve the quality of life for those suffering from injuries or vascular, autoimmune and degenerative disease. Based in Houston, Texas, Celltex is leading the United States into the future of regenerative medicine with its exclusive technology that precisely isolates, multiplies and stores individuals’ own adult adipose-derived mesenchymal stem cells (MSCs) for use in stem cell therapy. MSCs are taken directly from an individual’s fat in a simple procedure performed by a licensed U.S. physician. The cells are then sent to a Celltex laboratory where they are processed, multiplied to therapeutic levels and banked. When the patient is in need of their own stem cells, Celltex releases the cells to independent physicians in approved facilities in Mexico who administer the safe and effective stem cell therapy in a state-of-the-art facility. Celltex is committed to expanding the use of adult stem cell therapy for all and is currently working with leading American academic institutions on several clinical trials that will help secure the future of regenerative medicine here in the United States. For more information about Celltex Therapeutics Corporation, please visit www.celltexbank.com.
